Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down Syndrome

Objective Virtually all adults with Down syndrome (DS) have neuropathological manifestations of Dementia in Alzheimer's disease (DAD) but not all develop clinical psychopathology. The effect of allelic variants of Apolipoprotein (APOE) gene in development and progression of DAD and mortality in...

Full description

Saved in:
Bibliographic Details
Published in:International journal of geriatric psychiatry Vol. 23; no. 11; pp. 1134 - 1140
Main Authors: Prasher, V. P., Sajith, S. G., Rees, S. D., Patel, A., Tewari, S., Schupf, N., Zigman, W. B.
Format: Journal Article
Language:English
Published: Chichester, UK John Wiley & Sons, Ltd 01-11-2008
Wiley
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Virtually all adults with Down syndrome (DS) have neuropathological manifestations of Dementia in Alzheimer's disease (DAD) but not all develop clinical psychopathology. The effect of allelic variants of Apolipoprotein (APOE) gene in development and progression of DAD and mortality in persons with DS is examined. Methods Recruited participants with DS underwent two to 14 sequential assessments over a follow up period of 6 years on average and their APOE genotype determined. Dementia statuswas confirmed as recommended by the Working Group for the Establishment of Criteria forthe Diagnosis of Dementia in Individuals with Intellectual Disability. Results APOE genotype results were available for 252 individuals. Participants with APOE ε4 allele had significantly higher risk of developing DAD (HR = 1.8, 95% CI: 1.12–2.79), had an earlier onset of DAD (55.0 vs 57.0 years; p = 0.0027) and a more rapid progression to death compared with participants with ε3 allele (4.2 years vs. 5.4 years, respectively, p = 0.048). In non‐demented persons with DS, ε4 allele was associated with earlier death by 17 years (mean survival age, 55.7 vs. 72.7 years; HR = 5.9, 95% CI: 1.7–21.3). Conclusions This study highlights the relationship of APOE genotype to morbidity and mortality in persons with DS which has important clinical implications. We recommend screening for APOE genotype in persons with DS to identify those at risk of DAD and premature death. Further research is required to investigate the underlying reasons for the early mortality in non‐demented DS persons with an ε4 allele. Copyright © 2008 John Wiley & Sons, Ltd.
Bibliography:NIH - No. R01-AG014763; No. P01-HD35897; No. R01-HD37425
National Down Syndrome Society in collaboration with the NICHD
NYS
istex:EC93A01DFF8A6F3B50EF98358A1D6ED8D2532095
ark:/67375/WNG-VN5WS3W1-G
ArticleID:GPS2039
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0885-6230
1099-1166
DOI:10.1002/gps.2039